Northwestern Medicine scientists have uncovered key details about a group of rare but serious blood disorders, which may help inform potential treatments, according to a study published in the Journal ...

J&J JNJ announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended granting label expansion ...

A combination featuring Exelixis’ experimental drug zanzalintinib has beaten Bayer’s gastrointestinal cancer med Stivarga in ...

A study found another potential benefit of the weight loss drugs: lowered risk of chronic conditions. GLP-1 agonist medications such as Ozempic and Wegovy are in high demand, largely due to their ...

New data from GoodRx Research reveals just how inadequate and restrictive prescription insurance has become. Medicaid, often ...

MacMillan has been named a Distinguished Scholar in the Princeton Branch of the Ludwig Institute for Cancer Research, which ...

Some research, including a 2015 review in the Journal of Veterinary Science & Toxicology, suggests that long-term exposure to low levels of drug residue in meat could increase the risk of cancer ...

Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game. The deal announced by Bristol ...

Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment. Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE ...

Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University ... The Common Terminology Criteria for Adverse Events (version 5.0) were utilized to evaluate drug toxicity.

An ‘AI scientist’, working in collaboration with human scientists, has discovered that combinations of cheap and safe drugs could be effective at treating breast cancer The researchers, led by the ...

The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- advanced or metastatic breast cancer previously ...